1
|
Li K, Guo X, Qin F, Xiong Z, Zhao L, Yu J. Identification of the cytochrome P450 enzymes involved in the oxidative metabolism of trantinterol using ultra high-performance liquid chromatography coupled with tandem mass spectrometry. RSC Adv 2018; 8:34764-34772. [PMID: 35548639 PMCID: PMC9086916 DOI: 10.1039/c8ra06219f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 10/04/2018] [Indexed: 11/24/2022] Open
Abstract
Trantinterol is a novel β2-adrenoceptor agonist used for the treatment of asthma. This study aimed to identify the cytochrome P450 enzymes responsible for the metabolism of trantinterol to form 4-hydroxylamine trantinterol (M1) and tert-butyl hydroxylated trantinterol (M2), which was achieved using the chemical inhibition study, followed by the metabolism study of trantinterol in a panel of recombinant CYPs, as well as the kinetic study with the appropriate cDNA-expressed P450 enzymes. A highly selective and sensitive ultra high-performance liquid chromatography tandem mass spectrometry method was developed and validated for the simultaneous determination of M1 and M2. The inhibition study suggested that CYP2C19 and CYP3A4/5 were involved in the formation of M1 and M2, and CYP2D6 only contributed to the formation of M1. Assays with cDNA-expressed CYP enzymes further showed that the relative contributions of P450 isoforms were 2C19 > 3A4 > 2D6 > 2E1 for the formation of M1, and 3A4 > 2C19 > 2D6 for the formation of M2. The enzyme kinetic analysis was then performed in CYP2C19, CYP2D6 and CYP3A4. The kinetic parameters were determined and normalized with respect to the human hepatic microsomal P450 isoform concentrations. All the results support the conclusion that CYP3A4 and CYP2C19 are the major enzymes responsible for formation of M1 and M2, while CYP2D6 and CYP2E1 also engaged to a lesser degree. The results imply that potential drug–drug interactions may be noticed when trantinterol is used with CYP2C19 and CYP3A4 inducers or inhibitors, and we should pay attention to this phenomenon in clinical study. The first report on the characterization of the main CYP450 enzymes and the kinetic study involved in trantinterol metabolism.![]()
Collapse
Affiliation(s)
- Kunjie Li
- Department of Analytical Chemistry
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Xingjie Guo
- Department of Analytical Chemistry
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Feng Qin
- Department of Analytical Chemistry
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Zhili Xiong
- Department of Analytical Chemistry
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Longshan Zhao
- Department of Analytical Chemistry
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Jia Yu
- Department of Analytical Chemistry
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| |
Collapse
|
2
|
Zhou T, Zeng D, Zhao T, Yang Y, Liu S, Wu J, Xu L, Tan W. In vivo metabolism study of (R)-bambuterol in humans using ultra high performance liquid chromatography with tandem mass spectrometry. J Sep Sci 2016; 39:2896-906. [PMID: 27273913 DOI: 10.1002/jssc.201600424] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 05/05/2016] [Accepted: 05/23/2016] [Indexed: 11/08/2022]
Abstract
(R)-Bambuterol, a selective β2-adrenoceptor agonist, has been approved as a new drug for the treatment of asthma and chronic obstructive pulmonary disease by the China Food and Drug Administration and is currently under phase I clinical trials. In this study, a combined method based on ultra high performance liquid chromatography with triple quadrupole mass spectrometry and ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry was employed for the identification of the major metabolites of (R)-bambuterol in human plasma and urine after an oral dose of 10 mg. The metabolites were separated by gradient elution program and different sample preparation methods were compared. Totally, 12 metabolites of (R)-bambuterol were identified, including four metabolites in plasma and all 12 metabolites in urine. Among these, four metabolites are reported for the first time. The possible metabolic pathways of (R)-bambuterol were subsequently proposed. The results indicated that (R)-bambuterol was metabolized via hydrolysis, demethylation, oxygenation, glucuronidation, and sulfation pathways in vivo. This study revealed that this combined method was accurate and sensitive to identify the possible metabolites and to better understand the metabolism of (R)-bambuterol in vivo.
Collapse
Affiliation(s)
- Ting Zhou
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| | - Dan Zeng
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| | - Ting Zhao
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| | - Yang Yang
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| | - Shan Liu
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| | - Jie Wu
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| | - Ling Xu
- Keyharma Biomedical Inc, Songshan Lake Science and Technology Industry Park, Dongguan, China
| | - Wen Tan
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China.,Pre-incubator for Innovative Drugs and Medicine, South China University of Technology, Guangzhou, China.,Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou, China
| |
Collapse
|
3
|
Wang Y, Qin F, Xiong Z, Fu X, Ma C. An LC-MS/MS method for simultaneous determination of trantinterol and its major metabolite in rat plasma and its application to a comparative pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 1000:163-8. [PMID: 26245359 DOI: 10.1016/j.jchromb.2015.07.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 07/06/2015] [Accepted: 07/08/2015] [Indexed: 11/26/2022]
Abstract
Trantinterol is a novel β2-adrenoceptor agonist, currently undergoing clinical trials for the treatment of asthma. We developed and validated an liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of trantinterol and its major metabolite, 1-carbonyl trantinterol (SPFFCOOH), in rat plasma. Aliquots (100μL) of heparinized plasma samples were processed by protein precipitation with acetonitrile. Chromatographic separation used an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm) and acetonitrile-0.1% formic acid (20:80, v/v) as mobile phase, at a flow rate of 0.25mL/min. The detection was performed on a triple-quadrupole tandem mass spectrometer with multiple-reaction monitoring (MRM) mode via electrospray ionization (ESI) source. The precursor-to-product ion transitions m/z 310.9→m/z 237.9 for trantinterol, m/z 324.9→m/z 251.9 for SPFFCOOH and m/z 368.0→m/z 294.0 for bambuterol (internal standard, IS) were used for quantification. The calibration curves were obtained in the concentration of 0.25-100ng/mL for both trantinterol and SPFFCOOH. The intra- and inter-day precision (relative standard deviations, RSD) values were below 15% and accuracy (relative error, RE) was from -4.3% to 6.6% at all quality control (QC) levels. The method was successfully applied to compare the pharmacokinetics of trantinterol and SPFFCOOH in male and female Wistar rats after a single oral administration of trantinterol.
Collapse
Affiliation(s)
- Yanjuan Wang
- School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Feng Qin
- School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Zhili Xiong
- School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Xiaohuan Fu
- Jiangsu Kanion Pharmaceutical Co., Ltd, 58 Haichang South Road, Xinpu District, Lianyungang 222001, PR China
| | - Chao Ma
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, PR China.
| |
Collapse
|